Table 3.
Thyroid function tests in the two treatment groups before, during and 12 mo after treatment
| Group |
Before treatment |
During treatment |
After treatment |
||||||||||
| n | TGA1 | TPOAb2 | TSH3 | FT34/FT45 | TGA1 | TPOAb2 | TSH3 | FT34/FT45 | TGA1 | TPOAb2 | TSH3 | FT34/FT45 | |
| IFN-mono-therapy | 21 | 0 | 0 | 1 | 0 | 3 | 5 | 3 | 0 | 0 | 0 | 0 | 0 |
| IFN/ribavirin-combined treatment | 40 | 0 | 0 | 0 | 0 | 5 | 2 | 3 | 1 | 1 | 0 | 0 | 0 |
| Peginterferon-α + ribavirin | 62 | ND | 1 | 0 | ND | ND | 7 | 6 | ND | ND | 3 | 0 | ND |
| Total | 123 | 0 | 1 | 1 | 0 | 8 | 14 | 12 | 1 | 1 | 3 | 0 | 0 |
1
Thyroglobulin antibody (normal range < 50 U/L);
2
Thyroid peroxidase antibody (normal range < 35 IU/mL);
3
Thyroid-stimulating hormone (normal range 0.3-4.2 mU/L);
4
Free triiodothyronine (normal range: 1.8-4.6 ng/L);
5
Free thyroxine (normal range 7-19 ng/L). ND = not determined.